3 ms·

It is impressive and encouraging, but does not shorten the safety period. It may still come out in a year or two (or ten) that this increases the chance for som

It is impressive and encouraging, but does not shorten the safety period. It may still come out in a year or two (or ten) that this increases the chance for some autoimmune disease in a problematic way, or causes some other problem. The vaccine was created quickly, but as far as I understand we are now better at evaluating safety yet -- the 3-10 years safety study would still have been practiced if we weren't in the middle of a pandemic. The result of not enough testing can be fatal, see e.g. [0] [0] https://www.sciencemag.org/news/2019/04/dengue-vaccine-fiasco-leads-criminal-charges-researcher-philippines https://www.sciencemag.org/news/2019/04/dengue-vaccine-fiasc...

CorrectHorseBat 6y ago
I don't see the relevance of that article, that is a known side effect of dengue immunity and has nothing to do with the vaccine itself.
- beagle3 6y ago
  It’s a known side effect of dengue immunity acquired through getting infected with it. The vaccine was approved hastily and without addressing this concern - it is not “a known side effect of dengue immunity” but a side effect of prior infection, avoiding which was the whole point of the vaccine. There is no reason to believe that SarsCOV2 infection has a similar problem (ADE) or causes a similar long term issue - but it is too new to be sure. And if it does have an ADE issue (or similar) it is possible the vaccine will trigger it like the virus (as happened with this particular dengue vaccine, but which can potentially not be an issue with a different vaccine) And it’s also possible that the antibodies matching the protein chosen will attack another similar protein in the body with some people - and will cause an autoimmune condition. It is unlikely, but possible. That’s why vaccine safety profiles are usually tested for years before approval for general population. These vaccines have had exactly 2 months wide scale safety evaluation. I am very hopeful they will turn out safe; but our knowledge of their safety profile is very far from our usual level at the time vaccines are approved, especially with respect to long term safety.

CorrectHorseBat 6y ago

I don't see the relevance of that article, that is a known side effect of dengue immunity and has nothing to do with the vaccine itself.

beagle3 6y ago
It’s a known side effect of dengue immunity acquired through getting infected with it. The vaccine was approved hastily and without addressing this concern - it is not “a known side effect of dengue immunity” but a side effect of prior infection, avoiding which was the whole point of the vaccine. There is no reason to believe that SarsCOV2 infection has a similar problem (ADE) or causes a similar long term issue - but it is too new to be sure. And if it does have an ADE issue (or similar) it is possible the vaccine will trigger it like the virus (as happened with this particular dengue vaccine, but which can potentially not be an issue with a different vaccine) And it’s also possible that the antibodies matching the protein chosen will attack another similar protein in the body with some people - and will cause an autoimmune condition. It is unlikely, but possible. That’s why vaccine safety profiles are usually tested for years before approval for general population. These vaccines have had exactly 2 months wide scale safety evaluation. I am very hopeful they will turn out safe; but our knowledge of their safety profile is very far from our usual level at the time vaccines are approved, especially with respect to long term safety.